Clinical Development and Regulatory Approval for 2-PAM Autoinjectors
The Department of Health and Human Services is procuring late-stage clinical development and regulatory approval for 2-PAM autoinjectors intended to treat organophosphate poisoning in both adult and pediatric populations. This includes the procurement of these autoinjectors for the SNS/CHEMPACK Program, which is crucial for emergency response to nerve agent exposure.
Can you win this contract?
Get your fit score, win probability, and required capabilities.
Contract Details
- Estimated Value
- est. $15M – $120MSimilar contracts award $33K to $970K (median $210K, 3,203 awards)Above typical range
- NAICS Codes
- Place of Performance
- WASHINGTON, DC, USA
Agency & Contact
Contracting Organization
- Agency
- HEALTH AND HUMAN SERVICES, DEPARTMENT OF
- Sub-Agency
- ASPR / DAAPPO / BARDA
Point of Contact
Key Dates
Description
BARDA seeks late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program. Erin Greninger,
Contracting Officer Alternative
Point of Contact Greg Smith Contracting ’NEILL HOUSE (No Street Address
2) WASHINGTON, DC 20515 USA to this opportunity. 75A50126R00002 Amend 0001.pdf
Get matched to contracts like this daily
Free AI-powered contract matching for your business.